Previous 10 | Next 10 |
Senior Medical Technology Executive to Enhance Company’s Strategic and Operations Capabilities HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, an...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company with a track record for innovation and cutting-edge technology, recently announced that it was granted a patent for its 12-lead electrocardiogram (“ECG”) smartwatch-based monitor designed to identify heart attacks and complex c...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity research and corporate access firm fo...
NEW YORK, NY / ACCESSWIRE / January 12, 2023 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Heartbeam. Toni had the pleasure of recently conducting the Int...
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that th...
HeartBeam ( NASDAQ: BEAT ) said it was granted European patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG). This patent offers protection for HeartBeam’s technology in multiple countries in Europe and has been validated ...
Patented Technology Provides Protection for HeartBeam AIMIGo ™ Credit Card-sized Device in European Market HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywher...
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has issued a letter to shareholders. The letter, signed by HeartBeam CEO and founder Branislav Va...
MedTech company HeartBeam, Inc ( NASDAQ: BEAT ) announced Thursday that it will start filing for its version 1 and version 2 HeartBeam AIMIGo telehealth solutions in early 2023. The company, which offers ECG-based telemedicine technology for heart attack detection, filed a so-called 5...
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD....
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...